RTC
PCVX icon

Riverview Trust Company’s Vaxcyte PCVX Stock Holding History

Riverview Trust Company’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-230
Closed -$8.69K – 485
2025
Q1 		$8.69K Sell
230
-6
-3% -$480 0.01% 573
2024
Q4 		$19.3K Hold
236
– – 0.02% 485
2024
Q3 		$27K Buy
+236
New +$21.3K 0.02% 353

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Riverview Trust Company's PCVX Position: Q2 2025 in Review

Riverview Trust Company sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 230 shares — an estimated $8.69K sold.

Riverview Trust Company first reported a position in PCVX in Q3 2024 and held it in 3 quarters. The position peaked at $27K in Q3 2024. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

  • Riverview Trust Company reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
  • Riverview Trust Company sold 230 Vaxcyte shares in Q2 2025, an estimated $8.69K.
  • Riverview Trust Company first reported a position in Vaxcyte in Q3 2024 and held it in 3 quarters.
  • Riverview Trust Company's Vaxcyte position peaked at $27K in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Riverview Trust Company's 13F filing for Q2 2025, filed 21 Jul 2025.